[go: up one dir, main page]

WO2013020136A3 - Traitement de lésion cérébrale traumatique - Google Patents

Traitement de lésion cérébrale traumatique Download PDF

Info

Publication number
WO2013020136A3
WO2013020136A3 PCT/US2012/049770 US2012049770W WO2013020136A3 WO 2013020136 A3 WO2013020136 A3 WO 2013020136A3 US 2012049770 W US2012049770 W US 2012049770W WO 2013020136 A3 WO2013020136 A3 WO 2013020136A3
Authority
WO
WIPO (PCT)
Prior art keywords
injury
hemorrhage
brain injury
cerebral
traumatic brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/049770
Other languages
English (en)
Other versions
WO2013020136A2 (fr
Inventor
Minyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHA MEDICAL UNIVERSITY
Original Assignee
CHA MEDICAL UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHA MEDICAL UNIVERSITY filed Critical CHA MEDICAL UNIVERSITY
Publication of WO2013020136A2 publication Critical patent/WO2013020136A2/fr
Publication of WO2013020136A3 publication Critical patent/WO2013020136A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode et un kit pour le traitement de lésion cérébrale traumatique, de concussion et/ou d'autres états impliquant le cerveau, la tête/le cou et/ou des lésions neurologiques. Plus spécifiquement, l'invention porte sur l'utilisation de l'érythropoïétine et de cellules souches dans le traitement d'états incluant, sans caractère limitatif, quadriplégie due à un hématome sous-dural traumatique, hémorragie de la protubérance, lésion cérébrale hypoxique, contusion cérébrale, paralysie cérébrale, hémiplégie, hémorragie sous-arachnoïdien, hémorragie cérébrale, hémorragie épidurale, infarctus cérébral, myélite transverse, lésion médullaire, lésion nerveuse périphérique, atrophie multisystémique et leurs combinaisons.
PCT/US2012/049770 2011-08-04 2012-08-06 Traitement de lésion cérébrale traumatique Ceased WO2013020136A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515272P 2011-08-04 2011-08-04
US61/515,272 2011-08-04

Publications (2)

Publication Number Publication Date
WO2013020136A2 WO2013020136A2 (fr) 2013-02-07
WO2013020136A3 true WO2013020136A3 (fr) 2013-07-11

Family

ID=47629947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049770 Ceased WO2013020136A2 (fr) 2011-08-04 2012-08-06 Traitement de lésion cérébrale traumatique

Country Status (2)

Country Link
KR (2) KR20130016127A (fr)
WO (1) WO2013020136A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
EP3418430B1 (fr) 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Biomarqueurs du sang permettant de prédire un dysfonctionnement cognitif persistant après traumatisme
US9314457B2 (en) * 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
CA2991529C (fr) * 2015-07-08 2021-01-05 Gilrose Pharmaceuticals, Llc Traitement du trouble du traitement du cortex pre-frontal, traitement d'une alteration de la demarche et d'un membre
KR102079225B1 (ko) * 2017-01-11 2020-02-19 의료법인 성광의료재단 뇌신경계 질환의 치료 또는 진단을 위한 표적 단백질로서 pcnt
WO2020172513A1 (fr) * 2019-02-22 2020-08-27 University Of South Florida Méthodes de traitement de lésion cérébrale traumatique
KR20220041315A (ko) * 2020-09-25 2022-04-01 주식회사 대웅 뇌졸중 치료용 세포치료제
WO2023148524A1 (fr) * 2022-02-03 2023-08-10 Surgere S.R.L. Tissu contenant des cellules souches mésenchymateuses et appareil, et méthode de promotion de propriétés anti-inflammatoires et antinociceptives et d'amélioration de la capacité de réparation d'un tissu contenant des cellules souches mésenchymateuses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237751A1 (en) * 2000-03-09 2007-10-11 University Of South Florida Human Cord Blood as a Source of Neural Tissue Repair of the Brain and Spinal Cord
US20080292597A1 (en) * 2004-07-29 2008-11-27 David A Steenblock Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases
US20100112038A1 (en) * 2002-12-31 2010-05-06 Axaron Bioscience Ag Methods of treating neurological conditions with hematopoeitic growth factors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237751A1 (en) * 2000-03-09 2007-10-11 University Of South Florida Human Cord Blood as a Source of Neural Tissue Repair of the Brain and Spinal Cord
US20100112038A1 (en) * 2002-12-31 2010-05-06 Axaron Bioscience Ag Methods of treating neurological conditions with hematopoeitic growth factors
US20080292597A1 (en) * 2004-07-29 2008-11-27 David A Steenblock Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRASSO,G. ET AL.: "Neuroprotection by erythropoietin administration after experimental traumatic brain injury.", BRAIN RESEARCH., vol. 1182, 2007, pages 99 - 105, XP022343050 *
LU,D. ET AL.: "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury.", JOURNAL OF NEUROTRAUMA., vol. 22, no. 9, 2005, pages 1011 - 1017, XP055081226 *
MAMMIS,A. ET AL.: "Erythropoietin as a neuroprotective agent in traumatic brain injury.", SURGICAL NEUROLOGY., vol. 71, 2009, pages 527 - 531, XP026045467 *
XIONG,Y. ET AL.: "Emerging treatments for traumatic brain injury.", EXPERT OPIN. EMERG. DRUGS., vol. 14, no. 1, 2009, pages 67 - 84 *

Also Published As

Publication number Publication date
KR20130016127A (ko) 2013-02-14
WO2013020136A2 (fr) 2013-02-07
KR20150018855A (ko) 2015-02-24

Similar Documents

Publication Publication Date Title
WO2013020136A3 (fr) Traitement de lésion cérébrale traumatique
Laxpati et al. Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials
WO2013061161A3 (fr) Nouvelles polythérapies destinées au traitement de troubles neurologiques
HK1203044A1 (en) Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
MX2012004638A (es) Modulacion de degeneracion de axones.
WO2013025997A3 (fr) Procédés de stimulation du cerveau pour le traitement d'une sensibilité centrale
WO2011091366A3 (fr) Procédés de traitement ou de prévention de la parodontite et maladies associées à la parodontite
IN2014DN00288A (fr)
IN2014DN00286A (fr)
IN2014MN00093A (fr)
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
PT2945632T (pt) Compostos de heterobiciclo-substituído-[1,2,4]triazolo[1,5-c quinazolin-5-amina adequados para o tratamento ou prevenção de distúrbios do sistema nervoso central
IN2014MN01378A (fr)
MX2012004053A (es) Sistemas, dispositivos y metodos para el tratamiento de desordenes y condiciones neurologicas.
WO2007117344A3 (fr) systemes et procedes de differenciation et/ou d'identification de regionS tissulaires innervees par des nerfs cibles a des fins diagnostiques et/ou therapeutiques
IN2014DN06792A (fr)
WO2014018881A8 (fr) Agents de modulation d'atx
TN2014000326A1 (en) Inhibitors of beta-secretase
BR112014024308A2 (pt) "composições compreendendo neuregulina para reduzir dor neuropática, e usos de neuregulina
WO2012064943A3 (fr) Composés inhibiteurs de métalloenzymes
CA2863417A1 (fr) Proteines immunitaires innees comme biomarqueurs pour une lesion du snc
BR112017018068A2 (pt) dispositivo de neuromodulação
WO2013055385A3 (fr) Méthodes de traitement de troubles liés à l'âge
WO2011130347A3 (fr) Procédés d'amélioration d'une régénération axonale
WO2012174488A3 (fr) Agents et méthodes de traitement de maladies ischémiques et d'autres maladies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12820282

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12820282

Country of ref document: EP

Kind code of ref document: A2